Slovenia

Krka insisted that its margins were “stable and high,” as the Slovenian firm reported another solid quarter.

J&J says it has “exhausted all current viable avenues” to get its antidepressant nasal spray Spravato reimbursed on England’s National Health Service, after NICE decided against re-appraising the drug following numerous funding rejections.

Krka has reaffirmed its full-year financial goals after a solid start to 2024, which included 8% revenue growth for its pharmaceutical products. Generics Bulletin examines the company’s sprawling global operations.

Delivering record annual sales and profits according to preliminary financial results, Slovenia’s Krka will soon look to set up shop in India via a new company established with local big player Laurus Labs.

Presenting nine-month financial results, Krka disclosed a new slate of strategic objectives stretching out until 2028 – including a tacit admission that its current EBITDA margin may not be sustainable.

Slovenian firm and significant Eastern European and Central Asian player Krka has reported encouraging preliminary financial results for the first six months of the year, ahead of the imminent publication of its complete financial results.

On the back of recently-announced initiatives and alliances to bolster its biosimilars business ahead of its upcoming spinoff from parent company Novartis, Sandoz has revealed a further investment of around $90m to construct a technical development center in Slovenia.

The proposed European Health Data Space aims to enable the seamless transition of health data sharing for certain purposes across the EU. A new report highlights how national variations in data storage and budgetary constraints may affect the initiative’s success.

Spurred on by “increasing global demand for biosimilar medicines,” Sandoz has revealed plans to invest at least $400m in building a new biologics production plant in Slovenia.

The latest notified body listing brings total number of EU designated Medical Device Regulation testing and certification organizations to 35.

Krka’s management discussed the firm’s latest perception of the European biosimilars market, as it reported financial results for the nine months to 30 September.

Krka has explained a near double-digit percentage point drop for its EBITDA margin, as it presented preliminary results for the first half of 2022.

Slovenia’s Krka surprised the market with nearly 10% group turnover growth in the first quarter, driven by increases in all six of its sales regions, “most key markets, and by all product and service groups.”

The latest designation of a notified body in the context of the MDR means that the EU only needs one more to make the landmark total of 30. It seems that this may be realized soon.

A round-up of European consumer health business news: Dermapharm sees 2021 sales rise on the back of increased vitamin D demand; Sanofi plans to launch Enzymatica's ColdZyme in Turkey; and Slovenia's Krka posts rise in OTC sales.

A round-up of the latest European consumer health business news: Romania's Biofarm targets double-digit growth in 2022; Slovenia's Medis strikes deal with Salix for new product launch; and the UK's Theramex acquired by Carlyle and PAI Partners.

Another notified body has been designated under the Medical Device Regulation as demand is predicted to rise steeply in anticipation of the 26 May 2024 MDR deadline for all products.

Slovenian firm Krka wishes to strengthen and optimize its vertically integrated business model over the next five years, just one of many goals just published by the company under a new business plan to 2026.

Having picked up five prescription marketing authorization approvals in the first half of 2021, Slovenian generics giant Krka will be hoping to build on stagnant prescription pharmaceuticals reported in preliminary financial results.

Slovenian firm Krka saw sales and profits down in the first quarter of 2021 as operations normalized to some degree following an extraordinary Q1 last year.